

Transformations of cyclic nonaketides by *Aspergillus terreus* mutants blocked for lovastatin biosynthesis at the *lovA* and *lovC* genes

John L. Sorensen,^a Karine Auclair,^b Jonathan Kennedy,^c C. Richard Hutchinson^c and John C. Vederas^{*a}

^a Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada. E-mail: john.vederas@ualberta.ca; Fax: 00 1 780 492 5475; Tel: 00 1 780 492 8231

^b Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 2K6, Canada. E-mail: karine.auclair@mcgill.ca; Fax: 00 1 514 398 3797; Tel: 00 1 514 398 2822

^c Kosan Biosciences Inc., 3832 Bay Center Place, Hayward, California 94545, USA. E-mail: hutchinson@kosan.com; Fax: 00 1 510 732 8401; Tel: 00 1 510 732 8400


Received 7th August 2002, Accepted 18th September 2002

First published as an Advance Article on the web 21st November 2002

Two mutants of *Aspergillus terreus* with either the *lovC* or *lovA* genes disrupted were examined for their ability to transform nonaketides into lovastatin **1**, a cholesterol-lowering drug. The *lovC* disruptant was able to efficiently convert dihydromonacolin L **5** or monacolin J **9** into **1**, and could also transform desmethylmonacolin J **15** into compactin **3**. In contrast, the *lovA* mutant has an unexpectedly active β -oxidation system and gives only small amounts of **1** upon addition of the immediate precursor **9**, with most of the added nonaketide being degraded to heptaketide **22**. Similarly, the *lovA* mutant does not accumulate the polyketide synthase product **5** and rapidly degrades any **5** added as a precursor via two cycles of β -oxidation and hydroxylation at C-6 to give **20**. The possible involvement of epoxides **21a** and **21b** in the biosynthesis of **1** was also examined, but their instability in fermentation media and fungal cells will require purified enzymes to establish their role.

Introduction

Lovastatin **1** (also known as mevinolin, monacolin K, and MevacorTM) is a potent cholesterol-lowering agent¹ and a precursor for synthesis of the widely-prescribed drug, simvastatin **2** (ZocorTM).² Its 6-desmethyl analogue, compactin **3** (also designated as ML-236B or mevastatin) can be converted by microbial oxidation to the 6 β -hydroxy derivative, pravastatin **4** (PravacholTM).^{3,2b} These compounds and certain fully synthetic mimics block (3*S*)-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the biosynthesis of cholesterol.¹⁻⁴



Biosynthetic studies on lovastatin **1** with fungi, such as *Aspergillus terreus*, show that its assembly via a polyketide pathway involves initial construction of dihydromonacolin L **5**. The cooperation of polyketide synthases (PKSs) encoded by the *lovB* and *lovC* genes (Fig. 1) accomplish the ca. 35 steps necessary to generate **5** (Scheme 1).^{5,6} In the absence of the LovC protein, which imparts enoyl reductase activity to the complex, the LovB iterative type I PKS enzyme generates truncated pyranones **6** and **7**.⁵ During normal biosynthesis, oxidative transformations of the PKS product **5** introduce a second double bond in the decalin (decahydronaphthalene) system and





Fig. 1 Lovastatin biosynthesis genes.

add the C-8 hydroxyl to form monacolin J **9**.⁷ The 2-methylbutyryl side chain is produced by a separate PKS encoded by *lovF*, and further used by LovD to directly acylate **9** and yield **1**.⁵ The function of LovA, a protein essential for the formation of **1**, is not fully understood, but it has sequence homology to P450 enzymes and is probably involved in the oxidative conversion of **5** to introduce the diene system present in **9**. Biosynthetic studies on compactin **3** using the fungus *Penicillium aurantiogriseum* indicate a labelling pattern analogous to that seen in lovastatin **1**,^{8a} but the genetic machinery required for the formation of **3** has not yet been reported. †

Preliminary studies using an *A. terreus* mutant with the *lovC* gene disrupted demonstrated that cyclic nonaketide precursors such as dihydromonacolin L **5** and monacolin J **9** could be transformed to lovastatin **1** by this organism.⁹ We now report full details of this work as well as transformations of other cyclic nonaketides by this mutant and by an *A. terreus* mutant having a disrupted *lovA* gene. The results suggest that gene

† The gene cluster for compactin **3** has recently been characterised (see ref. 8b).



Scheme 1 Biosynthesis of Lovastatin.

disruption can alter the profile of secondary metabolites in ways that cannot be easily predicted based solely on their function in a biosynthetic pathway.

Results and discussion

In order to probe the role of the *lovA* and *lovC* genes in the biosynthetic pathway, two *A. terreus* mutants were examined in which one of these genes was disrupted, thereby blocking the production of lovastatin **1**. In the first instance we employed an *A. terreus* mutant with its *lovC* gene disrupted. ‡ As mentioned above, the *lovC* gene and the LovC protein produced by it have previously been demonstrated to be necessary for the biosynthesis of dihydromonacolin L **5**.^{5,6} It has also been shown that heterologous expression of the lovastatin biosynthesis gene *lovB* in *Aspergillus nidulans* results in production of the truncated polyketide metabolites **6** and **7**.⁵ These appear to arise after failure to complete the proper enoyl reductase step at the

triketide stage. However, expression of both the *lovC* and *lovB* genes in *A. nidulans* results in complete biosynthesis of dihydromonacolin L **5**, thereby indicating that LovC is responsible for providing the required enoyl reductase function to the LovB PKS system. The structure of **5** produced by these cultures has been confirmed by spectroscopic techniques and X-ray crystallography (Fig. 2).

Biotransformations by *A. terreus lovC* mutant

Careful HPLC analysis of fermentation extracts of the *A. terreus* mutant deficient in the *lovC* gene confirmed that it did not produce any **5** or **1**. However the entire post-PKS machinery required to transform **5** into **1** would still be expected to be intact and functional. In order to test this, a series of biotransformation experiments were conducted. Initially, formation of the diketide side chain (under the control of *lovF* gene) and its esterification onto monacolin J **9** (under the control of *lovD* gene) to afford **1** were examined. Monacolin J **9** was added (EtOH solution) to fermentation cultures of *A. terreus lovC* mutant in mid-log phase. Ten hours later, the culture broth was extracted and examined for the presence of **1**. HPLC analysis

‡ For a detailed description of the construction of *A. terreus* disruptants and *A. nidulans* transformants see the supporting information for ref. 5.





Fig. 2 Crystal structure of **5** (top) and **21a** (bottom).

revealed that about 70% of **9** had been converted into **1**. This demonstrates that the lovastatin diketide synthase (LDKS) is present and fully functional, and unlike the lovastatin nonaketide synthase (LNKS *i.e.* LovB), does not require LovC for proper assembly of the diketide side chain.

The specificity of the late stage enzymes was probed by examining whether 6-desmethylmonacolin J **15** could be transformed into compactin **3** by the *A. terreus lovC* mutant. When **15** (obtained by the basic hydrolysis of **3**) was added to fermentation cultures of this mutant, **3** was isolated from the culture broth in 45% yield after purification. This demonstrates that the acyltransferase enzyme (LovD) can tolerate the lack of a methyl group at the C-6 position of monacolin J **9**. In a separate experiment ML-236C, the 6-desmethyl analogue of monacolin L **8**, was added to cultures of the *A. terreus lovC* mutant. However, no compactin **3** could be detected by HPLC in the extract of the culture broth. This result suggests that either the enzyme responsible for hydroxylation at C-8 has a stringent requirement for the C-6 methyl group, or that **8** and ML-236C are not intermediates on the biochemical route to **1** and **3**, respectively. The latter possibility may be more probable, as occurrence of **8** on the direct lovastatin biosynthetic pathway has been disputed and is still uncertain.¹⁰


To help determine if the *A. terreus lovC* disruptant could be used effectively to make dihydrolovastatin analogues, possible biotransformation of dihydromonacolin J **12** was examined.



Scheme 2 Syntheses of dihydromonacolin J **12** and dihydrolovastatin **14**.


Compound **12** could be synthesised in 4 steps from **1** as shown in Scheme 2. Basic hydrolysis of **1** gave **9**, which could be selectively protected with TBDMSCl in DMF to afford **10**. Selective hydrogenation of **10** using Ir(cod)py(Pcy₃)PF₆ catalyst¹¹ in MeOH generated **11** in 86% yield. Removal of the protecting group with buffered TBAF produced **12** in 34% overall yield from **1**. Intermediate **11** could also be acylated with (*S*)-2-methylbutyric anhydride¹² yielding **13** which, with subsequent removal of the protecting group, affords the target dihydrolovastatin **14** in 35% overall yield from **1**.¹³ Compound **12** was added to cultures of the *A. terreus lovC* disruptant, but formation of **14** could not be detected by extensive HPLC analysis of the culture broth using synthetic **14** as a standard. Dihydrolovastatin **14** has been previously isolated from the fermentations of wild type *A. terreus* in 8% yield relative to lovastatin **1**, as determined by HPLC.¹⁴ This earlier study in combination with the current results suggests that either disruption of *lovC* unexpectedly alters the capability of the organism to transform **12** to **14**, or that this conversion does occur, but with alteration of the metabolism which further transforms **14** and brings its concentration below our detection limit.

To verify that the post-PKS enzyme system required to oxidatively introduce the second double bond of the diene moiety is intact in the *A. terreus lovC* mutant, dihydromonacolin L **5** (isolated from *A. nidulans lovB + lovC*) was added to a fermentation of this organism and the broth extract was examined by HPLC for the presence of **1**. Precursor **5** was transformed into **1** in 40% isolated yield, thereby demonstrating that all the necessary post-PKS steps for lovastatin biosynthesis are present in this mutant (Scheme 3).



Scheme 3 *A. terreus lovC* biotransformations.

The substrate specificity of the post-PKS machinery could be further tested by attempted transformation of a dihydromonacolin L derivative **16** having an unsaturation in the upper ring (Scheme 4). Elimination from the methanesulfonates of **5** or **1**




Scheme 4 Synthesis of unsaturated analogues.

gave α,β -dehydrodihydromonacolin L **16** and α,β -dehydrolovastatin **17**, respectively.¹⁵ Addition of **15** to cultures of the *A. terreus lovC* disruptant followed after 10 hours by HPLC analysis of the culture showed no detectable trace of **17**, suggesting that changes in the upper ring are not tolerated. The results of successful biotransformation experiments with *A. terreus lovC* mutant are summarised in Scheme 3.

Biotransformations by *A. terreus lovA* mutant

The transformation of **5** to **8** requires at least one oxidative enzyme, and it seemed that the *lovA* gene product, whose sequence is similar to cytochrome P450 enzymes, could be involved in this process. In order to investigate this, the biotransformations performed by an *A. terreus* mutant disrupted at the *lovA* gene were examined. This organism would be expected to accumulate dihydromonacolin L **5**, as it has an intact PKS system (*i.e.* *LovB + LovC* enzymes) and it should lack the ability to produce **1**. HPLC analysis of cultures of *A. terreus lovA* disruptant did not reveal the presence of any **1** (as expected), but **5** could not be detected either. This unexpected result suggests that either the *A. terreus lovA* mutant does not have the ability to produce **5**, or that **5** is somehow further transformed by the fungus.


In order to determine the fate of **5**, ¹⁴C-dihydromonacolin L (produced by addition of sodium ¹⁴C-acetate to *A. nidulans lovB + lovC* cultures), was fed to cultures of *A. terreus lovA* mutant. The extract of the culture was fractionated by thin layer chromatography, and the band containing most of the radioactivity was isolated to yield a chromatographically homogeneous compound. Full structural assignment reveals that **20** is the major product of **5** in the *A. terreus lovA* disruptant. This compound presumably arises as a result of two cycles of β -oxidation,¹⁶ first yielding the octaketide **18** followed by the heptaketide **19**. This is then terminated by a P450 type hydroxylation at C-6 to produce **20** (Scheme 5). This process for



Scheme 5 Proposed pathway to **20**.

metabolising **5** does not appear to be unique to the *A. terreus lovA* mutant, as **20** was also isolated from extracts of the cultures of *A. nidulans lovB + lovC*, along with a small amount of the intermediate heptaketide **19**. Careful examination of the radioactive **5** obtained from this *A. nidulans* strain and used as the precursor for the biotransformation confirmed that it was not contaminated by **19** or **20**. Since β -oxidation is ubiquitous in fungi such as *Aspergillus*,¹⁶ and hydroxylation at C-6 is common in the metabolism of lovastatin **1**,¹⁷ **20** appears to arise from a widespread metabolic pathway in *Aspergillus* which is unrelated to lovastatin biosynthesis. Although this explains the lack of dihydromonacolin L **5** in the *A. terreus lovA* mutant cultures, it is perhaps surprising that blockage of a key oxidative enzyme on the route to lovastatin **1** should shunt the metabolism so completely.


Another well established mode of reaction of P450 enzymes is the epoxidation of a double bond such as that present in **5**.¹⁸ Hydroxylation with allylic rearrangement to directly form the proposed intermediate, α -hydroxy-3,5-dihydromonacolin L¹⁹ (Scheme 1), would actually be an unexpected reaction for this type of enzyme,²⁰ which alternatively may be capable of dehydrogenation of **5** directly to the diene system. In order to determine if the LovA enzyme could form an epoxide during biosynthesis of lovastatin, the two diastereomeric epoxides **21a** and **21b** were prepared from **5** by treatment with MCPBA, followed by separation of the stereoisomers by HPLC (Scheme 6).



Scheme 6 Synthesis of **21a** and **21b**.

The stereochemical assignment of the two epoxides was confirmed by X-ray crystallography of the α -isomer (Fig. 2). In a separate experiment, ¹⁴C labelled **5** was used in the synthesis so that the transformation of **21a** and **21b** could be followed by tracer analysis. Each ¹⁴C-labelled diastereomer was fed to separate cultures of *A. terreus lovA* mutant, which were subsequently analysed by thin layer chromatography with radioisotopic scanning (radio-TLC). If an epoxide were the product of the LovA enzyme and therefore a true intermediate on the pathway to lovastatin, then either **21a** or **21b** should presumably be converted through the rest of the post-PKS pathway to yield **1**. However, no radioactive **1** could be detected by radio-TLC analysis. Analogous experiments wherein **21a** and **21b** were fed separately to cultures of *A. terreus lovC* mutant, yielded similar results: no radioactive **1** could be detected. In all cases, none of the original epoxide could be detected or recovered. Control experiments show that the epoxides are quite sensitive to the culture media, and decompose to complex mixtures of polar compounds that are not easily extracted into organic solvents. Treatment of **21a** with the methyl ester of glycine results in rapid nucleophilic opening of the epoxide ring by the amino group (data not shown). Hence, it is likely that these epoxides can react with nucleophiles either in the media or in the fungal cells prior to exposure to post-PKS enzymes in the lovastatin pathway. Further experiments to determine the intermediacy of **21a** or **21b** will require purified enzymes.

To verify that the late stages of the post-PKS machinery are still functional in the *A. terreus lovA* mutant, monacolin J **9** was added to cultures of this organism. Examination of the extracts by HPLC allowed isolation of a trace amount (*ca.* 1%) of lovastatin **1** along with an additional metabolite. The latter was identified as **22**. Similar to the fate of **5**, compound **9** is primarily metabolised by β -oxidation enzymes to a truncated product. However in this case, the additional double bond in the decalin system appears to hinder hydroxylation at C-6. The biotransformations performed by *A. terreus lovA* mutant are summarised in Scheme 7.



Scheme 7 Transformations by *A. terreus lovA* mutant.

Conclusions

Biotransformations of nonaketides accomplished by mutants of *A. terreus* deficient in two lovastatin biosynthesis genes (*lovA* or *lovC*) have been examined, and the structures of the resulting metabolites were determined. The mutant disrupted at the *lovC* gene lacks the ability to produce dihydromonacolin L **5** or lovastatin **1**, but still contains a highly functional set of post-PKS enzymes. This is established by the ability of the *A. terreus lovC* mutant to effectively transform either **5** or monacolin J **9** into **1**. In addition, this organism can transform **15** into **3**, thereby demonstrating that it can accept a slightly modified substrate. This work suggests that it may be possible to use the *A. terreus lovC* mutant to convert a variety of precursors into lovastatin analogues. Studies to accomplish this are in progress. As different substrate analogues may exhibit varying transport properties and diverse efficiency of transformation, cell-free studies with purified enzymes will be critical for detailed understanding of the biochemical conversions.

The mutant of *A. terreus* disrupted at the *lovA* gene displays quite different characteristics. In contrast to the *lovC* mutant, its β -oxidation system is highly active, with the consequence that there is rapid degradation of exogenously-added nonaketides which are known to be intermediates on the biosynthetic route to lovastatin **1**. For example, only a small amount of monacolin J **9**, the immediate precursor of **1**, is converted into the target drug, with most of the added compound being oxidatively degraded to **22**. This *lovA* mutant also does not accumulate dihydromonacolin L **5** as expected, but rather metabolises it rapidly to **20**. The LovA protein, although resembling a P450 enzyme and clearly required for production of lovastatin **1**, may also be involved in generating compounds which exercise control over expression or operation of the β -oxidation system in *A. terreus*.

Experimental

General Experimental

All chemicals were purchased from Aldrich Chemical company (Madison, WI) or Sigma Chemicals (St. Louis, MO). All solvents, unless otherwise indicated, were HPLC grade and used as such. Dry CH_2Cl_2 was prepared by distilling under Ar from CaH_2 . Diazomethane was prepared as a diethyl ether solution from DIAZALD (*N*-methyl-*N*-nitrosotoluene-*p*-sulfonamide) according to Aldrich technical bulletin AL-113. Evaporation refers to removal of solvent under reduced pressure on a rotary evaporator. Preparative TLC was done on glass plates (20 × 20 cm) pre-coated (0.25, 0.5, 1.0 mm) with silica gel (EM Science, Kieselgel 60 F₂₅₄). Analytical TLC was done on glass plates (5 × 1.5 cm) pre-coated (0.25 mm) with silica gel (EM Science, Kieselgel 60 F₂₅₄). Compounds were visualized by exposure to UV light and by dipping the plates in a 1% $\text{Ce}(\text{SO}_4)_2 \cdot 4\text{H}_2\text{O}$ 2.5% $(\text{NH}_4)_2\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ in 10% H_2SO_4 followed by heating on a hot plate. Flash column chromatography was performed with Silicycle silica gel (60 Å, 230–400 mesh).

Preparative HPLC was performed on a RANIN Dynamax high performance liquid chromatograph employing a manual injector, fraction collector and single wavelength detector. Reversed phase HPLC was conducted utilizing a Waters radial compression module with a Bondapak C₁₈ 25 × 100 mm column (15–20 μm particle size) with a guard column of similar packing. The mobile phase for RP-HPLC typically consisted of 100% H_2O to 70% CH_3CN –30% H_2O over 25 min, linear gradient. Normal phase HPLC was done on the same system using a Waters radial compression Porasil silica gel column (125 Å, 25 × 100 mm). The NP-HPLC mobile phase employed was 30% EtOAc–70% hexane to 70% EtOAc–30% hexane over 27 min.

NMR spectra were recorded on a Varian Inova 600, Inova 300 or Unity 500 spectrometer. For ^1H (300, 500 or 600 MHz) δ values are referenced to CHCl_3 (7.24 ppm) and for ^{13}C (125.8 or 150.9 MHz) referenced to CDCl_3 (77.0 ppm).

Melting points are uncorrected and were determined on a Kauffman Block microscope or a Thomas-Hoover apparatus using open capillary tubes. Optical rotations were measured on a Perkin-Elmer 241 polarimeter with a micro cell (100 mm path length, 1 mL). IR spectra were recorded on a Nicolet Magna-IR 750 with a Nic-Plan microscope FT-IR spectrometer. Mass spectra were recorded on a Krator AEI MS-50 (HREIMS) and a ZabSpec Isomass VG (HRESMS).

Radioactivity was determined using standard liquid scintillation procedures in plastic 10 ml scintillation vials with a Beckman Ready-gel scintillation cocktail. The scintillation counter used was a Beckman LS 5000TD with automatic quench control to directly determine decompositions per minute (dpm) in the labelled samples against a quench curve prepared from Beckman ^{14}C quenched standards. Radiolabelled compounds were also detected by a TLC assay, using a Berthold LB2760 2D-TLC scanner.

Aspergillus nidulans growth media was prepared by dissolving 20 g of glucose, 20 g of yeast extract, 1 g of peptone and 1 mL of a 1 mg per mL solution of *p*-aminobenzoic acid in 1 L of distilled deionized water. *Aspergillus nidulans* production media was prepared by dissolving in 1 L of distilled deionized water 1 mL trace element solution (1.0 g $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 8.8 g $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 0.4 g $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.15 g $\text{MnSO}_4 \cdot 4\text{H}_2\text{O}$, 0.1 g $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$, 0.05 g $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$, 0.5 mL conc. HCl dissolved in 1 L H_2O), 100 mL of 10 × AMM (*Aspergillus* Minimal Media) salts (60 g NaNO_3 , 5.2 g KCl, 15.2 g KH_2PO_4 dissolved in 1 L of H_2O and adjusted to pH 6.5), 1 mL of a 1 mg per mL *p*-aminobenzoic acid solution, and 0.9 mL of cyclopentanone and autoclaving. After cooling to room temperature 2.5 mL of a sterile solution of 20% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ and 25 mL of a sterile 40% lactose solution was added to the above

flask. All biological media solutions and equipment were autoclaved at 121 °C and 15 psi of steam pressure for 15 min.

4a,5-Dihydromonacolin L 5

4a,5-Dihydromonacolin L 5 was isolated from a strain of *Aspergillus nidulans* expressing the lovastatin *lovB* and *lovC* biosynthesis genes following the cloning procedure described elsewhere.⁵ The typical isolation procedure is described below. 10 μL of a concentrated spore suspension was used to inoculate 1 L of *A. nidulans* growth media and the culture was incubated at 30 °C and 200 rpm for 4 days. The mycelia were harvested by filtering through sterile miracloth (Calbiochem) and were thoroughly rinsed with 2 L of 1% lactose solution. The wet mycelia were divided into 4 equal portions and used to inoculate 4 × 1 L of *A. nidulans* production media. Cultures were incubated at 30 °C and 200 rpm for 2 days, after which point the growth was supplemented with 1 g L⁻¹ sodium acetate added each day for an additional 5 days. The cultures were harvested by removing the mycelia by vacuum filtration and the combined broth (4 L) was acidified with 2 M HCl (pH < 2) and extracted with CH_2Cl_2 (2 × 1.5 L). The combined organic layers were dried (Na_2SO_4), filtered and evaporated to provide ca. 500 mg of crude extract which was fractionated by flash column chromatography to provide 300 mg of pure 4a,5-dihydromonacolin L 5 (typical yields, 50–70 mg L⁻¹ of production media).

^{14}C -4a,5-Dihydromonacolin L 5 was produced from 1 L of *A. nidulans* production culture fermented as described above, except that 250 μCi of sodium [^{14}C]acetate (fed as a 5 mL aqueous solution 4 times per day) was added in addition to the unlabelled sodium acetate. The culture was harvested and extracted as above and the crude extract (97 mg) was fractionated by preparative TLC to give 22.5 mg of pure ^{14}C -4a,5-dihydromonacolin L 5 with a specific activity of 0.185 μCi mg⁻¹. The ^1H NMR of the ^{14}C -4a,5-dihydromonacolin L 5 was identical to that of the unlabelled compound.

For unlabelled 5: mp 162–163°C, lit. mp 163–164 °C;²¹ $[\alpha]_{\text{D}}^{25} = +115$ (*c* 0.22, methanol), lit. $[\alpha]_{\text{D}}^{25} = +123.9$ (*c* 0.5, methanol); UV (MeCN solution) λ_{max} 228 nm (br 210–234); IR (microscope) 3391 (br m), 3018 (w), 2910 (s), 1713 (s), 1254 (s), 1062 (s), 1047 (s) cm⁻¹; HREIMS 306.21902 (306.21948 calcd. for C₁₉H₃₀O₃) (M⁺, 27%), 288.20876 (M – H₂O, 18%), 161.13299 (M – C₇H₁₃O₃, 100%), 105.07044 (C₈H₉⁺, 99%). ^1H NMR (600 MHz, CDCl_3) δ 5.57 (ddd, 1H, *J* = 9.8, 4.9, 2.7 Hz, H-3), 5.28 (d, 1H, *J* = 9.8 Hz, H-4), 4.67 (m, 1H, H-11), 4.38 (m, 1H, H-13), 2.72 (dd, 1H, *J* = 17.6, 5.13 Hz, H-14), 2.60 (ddd, 1H, *J* = 17.6, 3.7, 1.6 Hz, H-14), 2.21 (m, 1H, H-2), 2.00 (m, 1H, H-6), 1.95 (m, 1H, H-12), 1.89 (m, 1H, H-4a), 1.81–1.73 (m, 2H, H-10 and H-12), 1.62 (m, 2H, H-9), 1.58–1.42 (m, 5H, H-5, H-7, H-8a and H-10), 1.07 (dq, 1H, *J* = 11.9, 3.7 Hz, H-8), 0.97 (dq, 1H, *J* = 11.9, 3.0 Hz, H-8), 0.96 (d, 3H, *J* = 7.3 Hz, 6-CH₃), 0.82 (d, 3H, *J* = 6.9 Hz, 2-CH₃); ^{13}C NMR (125 MHz, CDCl_3) δ 170.4 (C-15), 132.6 (C-3), 131.6 (C-4), 76.1 (C-11), 62.8 (C-13), 41.4 (C-8a), 40.0 (C-8), 38.9 (C-5), 38.7 (C-14), 37.3 (C-4a), 36.1 (C-12), 33.2 (C-10), 32.3 (C-7), 32.0 (C-2), 27.5 (C-6), 23.7 (C-1), 23.6 (C-9), 18.2 (6-CH₃), 14.9 (2-CH₃).

Crystal data for 4a,5-dihydromonacolin L 5

Data were acquired on a Bruker P4/RA/SMART 1000 CCD diffractometer. All intensity measurements were performed using graphite monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). 4a,5-Dihydromonacolin L 5 (C₁₉H₃₀O₃) was obtained as white crystals, space group *P*2₁2₁2₁ (No. 19), *a* = 5.5947 (9), *b* = 9.6504 (17), *c* = 31.930 (6) Å, *V* = 1723.9 (5) Å³, *Z* = 4, *T* = –80 °C, $\rho_{\text{calcd}} = 1.181$ g cm⁻³, $\mu = 0.078$ mm⁻¹. 10870 reflections were measured, 3287 unique which were used in all least squares calculations, $R_1(F) = 0.0620$ (for 899 reflections with $F_o^2 \geq 2\sigma(F_o^2)$), $wR_2(F^2) = 0.2159$ for all unique reflections. The absolute stereochemistry cannot be directly determined from the X-ray data, but it is correct as shown based on transformation

of **5** to **1**. CCDC reference number 191453. See <http://www.rsc.org/suppdata/ob/b2/b207721c/> for crystallographic files in CIF or other electronic format.

Monacolin J 9

Monacolin J **9** was produced by the basic hydrolysis of lovastatin as follows. 200 mg of lovastatin **1** was placed in a 25 mL round bottomed flask and suspended in 10 mL of aqueous 1 M LiOH and heated at reflux overnight. The reaction was cooled to room temperature, acidified with 2 M HCl (pH < 2) and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic extracts were dried (Na₂SO₄), filtered and evaporated to give 243 mg crude residue which was dissolved in 25 mL toluene and lactonized by heating at reflux with a CaH₂ Soxhlet apparatus for one hour. After cooling to room temperature the solvent was evaporated and the residue (208 mg) was fractionated by flash column chromatography (40% EtOAc in hexanes) to give 140 mg (89% yield) pure monacolin J **9**.

$[α]_D^{25} = +17.3$ (*c* 0.14, CH₃OH); IR (microscope) 3236 (br s), 2927 (s), 2879 (s), 1707 (m), 1645 (m), 1451 (s), 1318 (s), 1093 (s), 1075 (s), 1060 (s), 1049 (s), 1026 (s), 973 (s), 858 (s) cm⁻¹; HREIMS [M]⁺ 320.19827 (320.19876 calcd. for C₁₉H₂₈O₄) 320.2 (2%), 302.2 (9%), 198.1 (58%), 157.1 (100%), 105.1 (41%); ¹H NMR (500 MHz, CD₃OD) δ 5.93 (d, 1H, *J* = 10.0 Hz, H-4), 5.75 (dd, 1H, *J* = 10.0, 6.2 Hz, H-3), 5.45 (br s, 1H, H-5), 4.23 (br dd, 1H, *J* = 6.5, 2.8 Hz, H-8), 9.92 (m, 1H, H-11), 3.79 (m, 1H, H-11), 3.79 (m, 1H, H-11), 3.79 (m, 1H, H-13), 3.68 (br t, 2H, *J* = 6.5 Hz, H-14), 2.38 (m, 2H, H-2, H-6), 2.13 (br dd, 1H, *J* = 12.1, 2.8 Hz, H-13), 1.92–1.68 (m, 4H, H-7, H_a-9, H_a-12), 1.67–1.50 (m, 3H, H-1, H_a-10, H_b-12), 1.41 (m, 1H, H_b-10), 1.31 (m, 1H, H-9), 1.18 (d, 3H, *J* = 7.4 Hz, 6-Me), 0.89 (d, 3H, *J* = 6.9 Hz, 2-Me); ¹³C NMR (125 MHz, CD₃OD) δ 190.0 (C-15), 134.1 (C-4), 133.2 (C-4_a), 130.6 (C-3) 130.0 (C-5), 71.7 (C-8), 69.2 (C-11), 65.9 (C-13), 60.1 (C-14), 45.4 (C-7), 41.0 (C-10), 39.8 (C-8_a), 37.6 (C-1), 37.1 (C-12), 35.6 (C-9), 32.1, 29.1 (C-2, C-6), 23.65 (6-Me), 14.3 (2-Me).

tert-Butyldimethylsilyloxymonacolin J 10

tert-Butyldimethylsilyloxymonacolin J **10** was prepared according to the procedure of Willard and Smith.¹² 100 mg (0.312 mmol) monacolin J and 106.2 mg (1.56 mmol, 5 eq.) imidazole were placed in a 10 mL round bottomed flask and dissolved in 4 mL dimethylformamide (DMF). To this was added 117 mg (0.78 mmol, 2.5 eq.) tert-butyldimethylsilyl chloride as a solution in 1 mL DMF. The reaction was stirred at room temperature for 18 hours, then diluted with 30 mL CH₂Cl₂ and extracted with 0.2 M HCl (1 × 10 mL). The organic layer was washed with H₂O (3 × 10 mL), dried (Na₂SO₄), filtered and evaporated to give 197.5 mg crude residue. The product was purified by flash column chromatography (20% EtOAc in hexanes) to give 100 mg (74% yield) tert-butyldimethylsilyloxymonacolin J **10**.

$[α]_D^{25} = -10.1$ (*c* 1.35, CH₂Cl₂); FTIR (cast) 3446 (br), 2954 (s), 1734 (s), 1254 (s), 1082 (s), 735(s) cm⁻¹; HREIMS [M]⁺ 434.28466 (434.28525 calcd. for C₂₅H₄₂O₄Si) 434.3 (7%), 359.2 (17%), 284.2 (24%), 159.1 (100%), 101.0 (59%); ¹H NMR (600 MHz, CDCl₃) δ 5.95 (d, 1H, *J* = 9.5 Hz), 5.77 (dd, 1H, *J* = 6, 9.5 Hz), 5.52 (s, 1H), 4.65 (m, 1H), 4.27 (q, 1H, *J* = 3.5 Hz), 4.21 (s, 1H), 2.58 (dd, 1H, *J* = 17.5, 4 Hz), 2.53 (ddd, 1H, *J* = 17.5, 3, 1.5 Hz), 2.42 (m, 1H), 2.35 (s, 1H, *J* = 6.5), 2.14 (dd, 1H, *J* = 12, 2.5 Hz), 1.91–1.72 (m, 6H), 1.69 (ddd, 1H, *J* = 15, 3 Hz), 1.45 (m, 2H), 1.17 (d, 3H, *J* = 7.5 Hz), 0.88 (d, 3H, *J* = 7 Hz), 0.86 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 170.5, 133.7, 131.3, 130.0, 128.4, 76.5, 65.3, 63.5, 39.3, 38.8, 36.9, 36.5, 35.8, 33.0, 30.8, 27.4, 25.7, 24.3, 23.8, 18.0, 14.0, -4.8, -4.9.

4a,5-Dihydro(tert-butyldimethylsilyloxy)monacolin J 11

The iridium complex Ir(cod)py(Pcy₃)PF₆ was synthesized

according to the procedure of Stork and Kahne.²² The selective reduction of tert-butyldimethylsilyloxymonacolin J **10** was achieved by modification of the procedure of DeCamp *et al.*¹¹ To a solution of tert-butyldimethylsilyloxymonacolin J **10** (0.103 g, 0.24 mmol) in CH₂Cl₂ (1.7 mL) was added MeOH (0.1 mL) and the Ir complex (2 mg, 2.5 μmol). The mixture was hydrogenated for 10 min. Analytical TLC displayed the presence of starting material, therefore more Ir complex (2 mg, 2.5 μmol) was added and the mixture hydrogenated for an additional 10 min. This process was repeated until no starting material remained by TLC (a total of 8 mg Ir complex was added). The mixture was passed through a pad of Fluorosil to remove the catalyst and the solvent was evaporated under reduced pressure to give 4a,5-dihydro(tert-butyldimethylsilyloxy)monacolin J **11** (105 mg, quant.) as a mixture (86 : 14) of the desired olefin and over-reduced tetrahydro material. The tetrahydro product was removed by flash column chromatography (50% EtOAc in hexanes) to give pure 4a,5-dihydro(tert-butyldimethylsilyloxy)monacolin J **11**.

$[α]_D^{25} = +76$ (*c* 1.20, CH₂Cl₂); FTIR (cast) 3463 (br), 1733 (s), 1253 (s) cm⁻¹; HREIMS [M]⁺ 436.30047 (436.30090 calcd. for C₂₅H₄₄O₄Si) 436 (1%), 418 (6%), 361 (28%), 343 (8%) and 75 (100%); ¹H NMR (300 MHz, CDCl₃) δ 5.61 (ddd, 1H, *J* = 9.7, 4.9, 2.6 Hz), 5.36 (d, 1H, *J* = 9.8 Hz), 4.66 (m, 1H), 4.27 (m, 1H), 4.16 (m, 1H), 2.59 (dd, 1H, *J* = 17.5, 4.3 Hz), 2.56 (ddd, 1H, *J* = 17.5, 3.5, 1.4 Hz), 2.52–1.01 (m, 20H), 1.19 (d, 1H, *J* = 7.4 Hz), 0.87 (m, 9H), 0.81 (d, 3H, *J* = 7.1 Hz), 0.06 (3 H, s) and 0.05 (3 H, s); ¹³C NMR (125 MHz, CDCl₃) δ 174.0, 170.3, 132.6, 131.0, 76.3, 69.8, 63.6, 41.8, 41.7, 39.3, 38.6, 37.6, 36.8, 35.6, 33.2, 31.3, 30.9, 26.7, 26.7, 25.7, 23.1, 21.0, 16.5, 14.9, 11.7, -4.8, -4.9.

4a,5-Dihydromonacolin J 12

A sample of 30.0 mg (0.071 mmol) 4a,5-dihydro(tert-butyldimethylsilyloxy)monacolin J **11** was dissolved in 4 mL THF in a 10 mL round bottomed flask and cooled to 0 °C. 20 μL (0.355 mmol, 5 eq.) glacial acetic acid was added, followed 10 min later by 100 μL of a 1 M solution of tetrabutylammonium fluoride (TBAF) in THF (0.100 mmol, 1.5 eq.). The reaction was stirred for 2 h at 0 °C, then warmed to room temp. and stirred for an additional 2 h. Analytical TLC displayed mostly starting material so an additional 100 μL of 1 M TBAF in THF was added and the reaction stirred at room temp. overnight. The solvent was evaporated and the residue was dissolved in 20 mL CH₂Cl₂ and extracted with 0.4 M CaCl₂ (1 × 10 mL), washed with H₂O (3 × 10 mL), dried (Na₂SO₄), filtered and evaporated to give 20.0 mg crude product. 4a,5-Dihydromonacolin J **12** was purified by flash column chromatography over silica gel (1–5% *i*-PrOH in CH₂Cl₂) to yield 13.6 mg (60% yield) pure product.

$[α]_D^{25} = +137.4$ (*c* 0.38, MeOH); FTIR (cast), 3361 (br), 2906 (s), 1703 (s), 1259 (s), 1039 (s) cm⁻¹; HREIMS [M]⁺ 322.21394 (322.2144 calcd. for C₁₉H₃₀O₄) 322.2 (1%), 286.2 (10%), 200.1 (18%), 159.1 (79%); ¹H NMR (600 MHz, CDCl₃) δ 5.60 (ddd, 1H, *J* = 9.7, 4.8, 2.6 Hz), 5.35 (d, 1H, *J* = 10.1 Hz), 4.68 (m, 1H), 4.36 (quintet, 1H, *J* = 3.7 Hz), 4.14 (d, 1H, *J* = 2.8 Hz), 2.71 (dd, 1H, *J* = 18.0, 5.1 Hz), 2.60 (ddd, 1H, *J* = 18.0, 3.8, 1.8 Hz), 2.01–1.90 (m, 3H), 1.82–1.20 (m, 16 H), 1.18 (d, 3H, *J* = 7.5 Hz), 0.83 (d, 3H, *J* = 7.0 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 170.4, 132.3, 131.5, 76.1, 67.1, 62.8, 42.7, 39.3, 39.0, 38.6, 37.0, 36.3, 32.8, 31.4, 29.7, 27.0, 23.0, 21.6, 15.0.

4a,5-Dihydro(tert-butyldimethylsilyloxy)lovastatin 13

A sample of 14.0 mg (0.032 mmol) 4a,5-dihydro(tert-butyldimethylsilyloxy)monacolin J **11** and 5 mg (0.041 mmol) 4-dimethylaminopyridine were placed in a 1 mL React-vial and dissolved in 0.5 mL pyridine. To this mixture was added 100 μL (93.4 mg, 0.50 mmol) (*S*)-2-methylbutyric anhydride and the reaction was stirred at room temperature for 72 hours. The reaction was diluted with 30 mL CH₂Cl₂ and washed with 1 M

HCl (1 × 10 mL). The organic layer was washed with H₂O (3 × 10 mL), dried (Na₂SO₄), filtered and evaporated to give ca. 50 mg of crude residue which was purified by flash column chromatography to give 11.9 mg (72% yield) of pure 4a,5-dihydro(*tert*-butyldimethylsilyloxy)lovastatin **13**.

$[\alpha]_D^{25} = +73$ (*c* 0.20, CHCl₃); FTIR (cast) 2295 (s), 1727 (s), 1253 (s), 1079 (s) cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.62 (ddd, 1H, *J* = 9.5, 4.5, 2.5 Hz), 5.36 (d, 1H, *J* = 9.5 Hz), 5.15 (d, 1H, *J* = 2.5 Hz), 4.55 (m, 1H), 4.25 (quintet, 1H, *J* = 3.5 Hz), 2.57 (dd, 1H, *J* = 17, 4.5 Hz), 2.52 (dd, 1H, *J* = 17, 1 Hz), 2.45 (m, 1H), 2.41 (m, 1H), 2.32 (q, 1H, *J* = 7 Hz), 2.27 (m, 1H), 2.02 (m, 1H), 1.89 (d, 1H, *J* = 15 Hz), 1.83–1.80 (m, 2H), 1.72–1.44 (m, 5H), 1.32–1.22 (m, 2H), 1.17 (d, 2H, *J* = 7 Hz), 1.10 (d, 3H, *J* = 7 Hz), 1.07 (d, 3H, *J* = 7.5 Hz), 0.93 (t, 3H, *J* = 7.5 Hz), 0.86 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 175.0, 170.1, 132.6, 131.0, 76.3, 69.8, 63.6, 41.8, 41.7, 39.3, 38.6, 37.6, 36.8, 35.6, 33.2, 31.3, 30.9, 26.8, 26.7, 26.6, 25.6, 23.1, 21.0, 17.9, 16.5, 16.4, 14.9, 11.7, -4.8, -4.9.

4a,5-Dihydrolovastatin 14

7.7 mg (0.0148 mmol) of **13** was dissolved in 1 mL of 10% HCl in MeOH, and stirred at room temp. for 1 hour. The reaction was diluted with 30 mL CH₂Cl₂ and extracted with NaHCO₃ (3 × 10 mL). The organic layer was washed with H₂O (3 × 10 mL), dried and evaporated to give 5.0 mg of **14**.

¹H NMR (300 MHz, CDCl₃) δ 5.62 (m, 1H), 5.35 (d, 1H, *J* = 9.6 Hz), 5.17 (m, 1H), 4.55 (m, 1H), 4.35 (m, 1H), 2.74 (d, 1H, *J* = 5.0 Hz), 2.68 (d, 1H, *J* = 5.0 Hz), 2.61 (dd, 1H, *J* = 3.8, 1.5 Hz), 2.52 (dd, 1H, *J* = 4.2, 1.5 Hz), 2.43 (d, 1H, *J* = 6.0 Hz), 2.4–2.2 (m, 2H), 2.05–1.75 (m, 6H), 1.70–1.40 (m, 10H), 1.15 (d, 3H, *J* = 7.0 Hz), 1.08 (d, 3H, *J* = 7.4 Hz), 0.88 (t, 3H, *J* = 8 Hz), 0.82 (d, 3H, *J* = 7.0 Hz).

6-Desmethylmonacolin J 15

A solution of compactin **3** (55 mg, 0.13 mmol) and LiOH (60 mg, 1.3 mmol) in H₂O (15 mL) was heated at reflux for one day. The reaction mixture was cooled in an ice bath, acidified with 2 M HCl (pH < 1) and extracted with EtOAc (5 × 30 mL) and CHCl₃ (4 × 20 mL). The combined organic extracts were dried (Na₂SO₄), filtered and evaporated. The resulting residue was taken up in toluene (60 mL) and heated at reflux in a Soxhlet containing CaH₂ for one hour. After cooling the toluene was evaporated and the residue fractionated by flash column chromatography (EtOAc, 100%) to yield 30 mg of **15** as a colorless oil (75%).

$[\alpha]_D^{25} = +78$ (*c* 0.15, CHCl₃); FTIR (cast) 3407 (br s), 2928 (s), 1710 (s), 1256 (s), 1075 (s), 754 (s); HREIMS [M]⁺ 306.18245 (306.18311 calcd. for C₁₈H₂₆O₄); ¹H NMR (500 MHz, CDCl₃) δ 5.92 (d, 1H, *J* = 9.6 Hz), 5.71 (dd, 1H, *J* = 9.6, 6.0 Hz), 5.52 (br d, 1H, *J* = 2.1 Hz), 4.69 (m, 1H), 4.52 (m, 1H), 4.21 (br s, 1H), 2.67 (dd, 1H, *J* = 17.7, 5.0 Hz), 2.59 (ddd, 1H, *J* = 17.7, 3.7, 1.7 Hz), 2.31 (m, 2H), 2.14 (m, 2H), 1.96 (m, 2H), 1.82–1.62 (m, 5H), 1.53–1.39 (m, 2H), 0.88 (d, 3H, *J* = 7.0 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 170.8, 133.3, 133.0, 128.3, 123.6, 76.2, 64.4, 62.6, 38.8, 38.5, 36.4, 36.1, 32.6, 30.8, 29.1, 23.8, 20.3, 13.9.

α,β-Dehydro-4a,5-dihydromonacolin L 16

A sample of 18.4 mg (0.060 mmol) 4a,5-dihydromonacolin L **5** was dissolved in 0.5 mL CH₂Cl₂. To this solution was added 7.1 μL (10.3 mg, 0.90 mmol, 1.5 eq.), methanesulfonyl chloride and 2.5 μL (18.2 mg, 0.18 mmol, 3 eq.) triethylamine and the reaction was stirred at room temp. 1 hour. The reaction mixture was diluted with 30 mL CH₂Cl₂ and extracted with 0.2 M HCl (1 × 10 mL) and satd. NaHCO₃ (1 × 10 mL). The organic layer was washed with H₂O (3 × 10 mL), dried (Na₂SO₄), filtered and evaporated to give 21.0 mg crude product. The product was fractionated by preparative TLC (hexane–

EtOAc, 1 : 1) to give 10 mg (60%) pure α,β-dehydro-4a,5-dihydromonacolin L **16**.

$[\alpha]_D^{25} = +8.6$ (*c* 1.00, CH₂Cl₂); FTIR (cast) 2915 (s), 1717 (s), 1389 (s), 1248 (s), 818 (s) cm⁻¹; HREIMS [M]⁺ 288.20866 (288.20892 calcd. for C₁₉H₂₈O₂) (19%), 273.2 (17%), 228.2 (22%), 176.1 (85%), 161.1 (71%), 105.1 (100%); ¹H NMR (600 MHz, CDCl₃) δ 6.85 (ddd, 1H, *J* = 9.5, 9.5, 4.4 Hz), 6.00 (d, 1H, *J* = 9.8 Hz), 5.57 (ddd, 1H, *J* = 9.7, 4.7, 2.8 Hz), 5.28 (d, 1H, *J* = 9.8 Hz), 4.41 (dddd, 1H, *J* = 12.3, 12.3, 7.6, 4.7 Hz), 2.33 (m, 2H), 2.21 (m, 1H), 2.11 (m, 1H), 1.91–1.87 (m, 2H), 1.62–1.41 (m, 8H), 1.34–1.22 (m, 2H), 1.08 (m, 1H), 0.99 (dd, 1H, *J* = 10.3, 2.6 Hz), 0.96 (d, 3H, *J* = 7.3 Hz), 0.83 (d, 3H, *J* = 7.0); ¹³C NMR (150 MHz, CDCl₃) δ 164.3, 144.8, 132.5, 131.6, 121.3, 78.0, 41.1, 39.6, 38.3, 38.2, 37.0, 32.0, 31.8, 31.5, 29.0, 27.1, 23.2, 17.7, 14.6.

α,β-Dehydrolovastatin 17

33.0 mg (0.082 mmol) lovastatin **1** was placed in a 25 mL round bottomed flask and dissolved in 3 mL CH₂Cl₂. To this solution was added 34.7 μL (25 mg, 0.249 mmol, 3 eq.) triethylamine, followed by 9.6 μL (14 mg, 0.123 mmol, 1.5 eq.) methanesulfonylchloride and the reaction was stirred at room temp. for one hour. The reaction was diluted with CH₂Cl₂ and extracted with 0.1 M HCl (1 × 10 mL) and satd. NaHCO₃ (1 × 10 mL), washed with H₂O (3 × 10 mL), dried (Na₂SO₄) and filtered to give 40.4 mg of crude residue which was fractionated by flash column chromatography to give 33.7 mg pure α,β-dehydrolovastatin **17**.

$[\alpha]_D^{25} = +136.4$ (*c* 3.30, CH₂Cl₂); FTIR (cast) 2963 (s), 1723 (s), 1383 (s), 1247 (s), 818 (s) cm⁻¹; HREIMS [M]⁺ 386.24530 (386.24570 calcd. for C₂₄H₃₄O₄) 386.2 (2%), 284.2 (17%), 198.1 (64%), 159.1 (100%); ¹H NMR (600 MHz, CDCl₃) δ 6.83 (ddd, 1H, *J* = 9.8, 6.1, 2.4 Hz), 5.98 (ddd, 1H, *J* = 9.7, 2.6, 0.9 Hz), 5.97 (d, 1H, *J* = 10.5 Hz), 5.76 (dd, 1H, *J* = 9.5, 6.1 Hz), 5.50 (m, 1H), 5.36 (d, 1H, *J* = 3.2 Hz), 4.31 (dddd, 1H, *J* = 11.5, 11.5, 5.3, 3.5 Hz), 2.42 (m, 1H), 2.37–2.30 (m, 3H), 2.25–2.19 (m, 2H), 1.96–1.87 (m, 3H), 1.69–1.59 (m, 3H), 1.51–1.28 (m, 4H), 1.08 (d, 3H, *J* = 7.0 Hz), 1.05 (d, 3H, *J* = 7.4 Hz), 0.87 (d, 3H, *J* = 7.0 Hz), 0.85 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (125 MHz, CDCl₃) δ 176.6, 164.2, 144.7, 133.0, 131.6, 129.7, 128.3, 121.5, 78.5, 67.7, 41.4, 37.3, 36.6, 32.7, 32.4, 30.7, 29.5, 27.4, 26.8, 24.2, 22.8, 16.2, 13.8, 11.7.

Heptaketide 19

Heptaketide **19** was isolated from cultures of *A. nidulans lovB + lovC* as follows. 4 L of *A. nidulans lovB + lovC* production cultures, fermented as described above for the isolation of **5**, were extracted with CH₂Cl₂ (2 × 1.5 L) WITHOUT acidification of the culture broth. The organic layer was dried (Na₂SO₄), filtered and evaporated to give ca. 50 mg of crude residue. Purification by flash column chromatography (EtOAc 100%) gave 6.5 mg of pure **19**.

$[\alpha]_D^{25} = +120.3$ (*c* 0.10, CHCl₃); FTIR (cast) 3020, 2952, 2915, 2860, 1696, 1445, 1411, 1377, 1310, 1297, 1267, 1238, 1211, 720 cm⁻¹; HREIMS [M]⁺ 236.1777 (236.1776 calcd. for C₁₅H₂₄O₂); ¹H NMR (500 MHz, CDCl₃) δ 5.57 (ddd, 1H, *J* = 10.0, 5.0, 3.0 Hz), 5.28 (d, 1H, *J* = 10.0 Hz), 2.42 (ddd, 1H, *J* = 15.5, 10.0, 5.0 Hz), 2.26–2.19 (m, 2H), 2.00 (m, 1H), 1.96–1.97 (m, 2H), 1.60–1.44 (m, 5H), 1.36 (m, 1H), 1.25 (dt, 1H, *J* = 13.0, 4.5 Hz), 1.10 (dq, 1H, *J* = 12.0, 4.0 Hz), 1.02–0.94 (m, 1H), 0.96 (d, 3H, *J* = 7.5 Hz), 0.82 (d, 3H, *J* = 7.0 Hz); ¹³C NMR (125 MHz, CDCl₃) δ 179.9, 132.3, 131.5, 41.0, 39.9, 38.9, 37.3, 32.3, 32.0, 31.9, 27.5, 23.8, 23.6, 18.2, 15.0.

β-Oxidation product 20

β-Oxidation product **20**, was isolated from a biotransformation experiment as follows. 1 L of *A. nidulans* growth media was inoculated with 10 mL of a concentrated suspension of *Aspergillus terreus lovA* spores and incubated at 30 °C and 200

rpm for 2 days. To the growing culture was added a solution of unlabelled 4a,5-dihydromonacolin L (30 mg) and 52.5 nCi (ca. 0.5 mg) of ^{14}C -4a,5-dihydromonacolin L in 6 mL EtOH. 0.5 mL of this dihydromonacolin L solution was added to the cultures three times a day until completely fed. After seven days total growth the mycelia were removed by vacuum filtration, the broth acidified with 2 M HCl (pH < 2) and extracted with CH_2Cl_2 (1 \times 1 L, 1 \times 0.5 L). The combined organic layers were dried (Na_2SO_4), filtered and evaporated to give 207.2 mg crude extract. The crude extract was fractionated by preparative TLC to give a fraction (26.3 mg) containing the majority of the radioactivity. A portion of this radioactive fraction was treated with CH_2N_2 (Et_2O solution), and fractionated by preparative TLC to isolate the β -oxidation product as the major radioactive component (1.7 mg, 3.4 nCi).

This same product could be isolated from the CH_2Cl_2 extract of *A. nidulans lovB + lovC* production cultures grown as described above. A portion (23.2 mg) of the crude CH_2Cl_2 extract was treated with CH_2N_2 (Et_2O solution) to give 26.1 mg crude methylated product which was fractionated by HPLC to give 2.2 mg pure β -oxidation product **20**.

FTIR (cast) 3297 (br), 3008 (s), 1737 (s), 1437 (m), 1223 (s), 1170 (s) cm^{-1} ; HREIMS 248.17729 (248.1763 calcd. for $\text{C}_{16}\text{H}_{24}\text{O}_2$) [M - H_2O] $^+$, 217.1 (18%), 192.1 (14%), 161.1 (100%), 119.1 (52%), 105.1 (78%); ^1H NMR (600 MHz, CDCl_3) δ 5.58 (ddd, 1H, $J = 9.5, 4.5, 2.5$ Hz, H-3), 5.30 (d, 1H, $J = 9.5$ Hz, H-4), 3.65 (s, 3H, OCH_3), 2.37 (ddd, 1H, $J = 15, 10, 5$ Hz, H-10_{a/b}), 2.24 (m, 1H, H-2), 2.18 (ddd, 1H, $J = 15, 9.5, 6.5$ Hz, H-10_{a/b}), 1.89 (m, 2H, H-9), 1.80, 1.78 (d, 1H, $J = 2.5, \text{H-4}_a$), 1.69, 1.67, 1.47, 1.23 (s, 3H, 6- CH_3), 1.02, 0.83 (d, 3H, $J = 7$ Hz, 2- CH_3); ^{13}C NMR (125 MHz, CDCl_3) δ 171.3, 132.9, 130.3, 71.2, 51.6, 47.1, 41.1, 41.0, 40.8, 39.2, 32.0, 31.9, 27.0, 26.1, 24.3, 14.8.

4a,5-Dihydromonacolin L epoxide **21a**, **21b**

A sample of 50.0 mg (0.163 mmol) dihydromonacolin L **5** was placed in a 10 ml round bottomed flask and dissolved in 4 mL of CHCl_3 under $\text{Ar}_{(\text{g})}$. To this solution was added dropwise 50.1 mg (0.244 mmol, 1.5 eq.) of an 85% preparation of *m*-chloroperbenzoic acid in benzoic acid dissolved in 1 mL of CHCl_3 . The reaction was stirred under $\text{Ar}_{(\text{g})}$ at room temperature for 90 min. The reaction was diluted with 25 mL of CH_2Cl_2 and extracted with 5% NaHSO_3 (1 \times 10 mL) and satd. NaHCO_3 (1 \times 10 mL), and washed with H_2O (3 \times 10 mL). The organic layer was dried (Na_2SO_4), filtered and evaporated to give 54.1 mg crude product which was fractionated by flash column chromatography (40% EtOAc in hexanes) to yield 11.3 mg of **21a** and 11.2 mg of **21b** (44% total yield of pure **21a** and **21b**).

For 4a,5-dihydromonacolin L α -epoxide **21a**: $[a]_{\text{D}}^{25} = +90$ (c 0.95, CHCl_3); FTIR (cast) 3392 (br), 2915 (s), 2876 (s), 1709 (s), 1257 (s), 1044 (s), 842 (s); HREIMS $[\text{M}]^+$ 322.21451 (322.21442 calcd. for $\text{C}_{19}\text{H}_{30}\text{O}_4$) 322 (5%), 307 (5%), 191 (48%), 179 (100%), 95 (65%); ^1H NMR (500 MHz, CDCl_3) δ 4.63 (dddd, 1H, $J = 11.0, 11.0, 7.6, 3.8$ Hz), 4.36 (m, 1H), 2.98 (d, 1H, $J = 2.4$ Hz), 2.72 (d, 1H, $J = 3.7$ Hz), 2.69 (d, 1H, $J = 5.0$ Hz), 2.61 (dd, 1H, $J = 3.6, 1.7$ Hz), 2.56 (dd, 1H, $J = 3.7, 1.7$ Hz), 2.30 (m, 1H), 2.05 (m, 2H), 1.93 (m, 2H), 1.8–1.6 (m, 2H), 1.6–1.3 (m, 10H), 0.95 (d, 3H, $J = 7.1$ Hz), 0.89 (d, 3H, $J = 7.2$ Hz); ^{13}C NMR (125 MHz, CDCl_3) δ 170.4, 76.0, 62.8, 58.8, 57.5, 38.6, 38.8, 37.4, 36.3, 36.2, 36.1, 33.0, 32.0, 30.3, 27.6, 23.9, 23.7, 18.1, 10.2.

For 4a,5-Dihydromonacolin L β -epoxide **21b**: ^1H MNR (600 MHz, CDCl_3) δ 4.65 (dddd, 1H, $J = 11.5, 11.5, 7.3, 4.0$ Hz), 4.37 (m, 1H), 3.17 (dd, 1H, $J = 3.9, 5.5$ Hz), 2.91 (d, 1H, $J = 3.9$ Hz), 2.71 (dd, 1H, $J = 17.6, 5.0$ Hz), 2.60 (ddd, 1H, $J = 17.6, 3.7, 1.7$ Hz), 2.15 (m, 1H), 2.05 (m, 1H), 1.90 (m, 2H), 1.75 (m, 2H), 1.65–1.40 (m, 8H), 1.20 (m, 2H), 0.97 (d, 3H, $J = 7.2$ Hz), 0.92 (d, 3H, $J = 7.1$ Hz); ^{13}C NMR (125 MHz,

CDCl_3) δ 170.2, 75.8, 62.8, 58.2, 57.0, 41.5, 38.6, 37.6, 35.9, 35.6, 34.6, 33.2, 31.7, 28.9, 26.9, 23.2, 22.7, 18.0, 9.5.

Crystal data for 4a,5-dihydromonacolin L α -epoxide **21a**

Data were acquired on a Bruker P4/RA/SMART 1000 CCD diffractometer. All intensity measurements were performed using graphite monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). 4a,5-Dihydromonacolin L α -epoxide **20a** ($\text{C}_{19}\text{H}_{30}\text{O}_4$) was obtained as white crystals, space group $P2_12_12_1$ (No. 19), $a = 5.5318$ (11), $b = 9.7123$ (19), $c = 32.163$ (7) Å, $V = 1728.0$ (6) Å 3 , $Z = 4$, $T = -80$ °C, $\rho_{\text{calcd}} = 1.239$ g cm^{-3} , $\mu = 0.085$ mm $^{-1}$. 9765 reflections measured, 3482 unique which were used in all least squares calculations, $R_1(F) = 0.0538$ (for 2478 reflections with $F_o^2 \geq 2\sigma(F_o^2)$), $wR_2(F^2) = 0.1044$ for all unique reflections. The absolute stereochemistry of **21a** cannot be directly determined from the data, but it is correct as shown based on conversion of **5** to **1** and to **21a**. CCDC reference number 191454. See <http://www.rsc.org/suppdata/ob/b2/b207721c/> for crystallographic files in CIF or other electronic format.

β -Oxidation product **22**

β -Oxidation metabolite **22** was isolated as follows. *A. terreus lovA* spores were used to inoculate flasks (2 \times 100 mL) of *A. nidulans* growth media after 4 days the mycelia were harvested by filtration and transferred to *A. nidulans* production media (2 \times 100 mL). After 48 hours, a solution of monacolin J in EtOH (30 mg in 3.0 ml EtOH) was administered in intervals (0.5 mL of the above solution every 12 hours until completely fed). After seven days total growth in the production media, the culture broth was harvested by vacuum filtration. The combined broth was acidified and extracted with EtOAc (2 \times 100 ml). The combined organic extracts were dried, filtered and evaporated to give 42.0 mg crude extract. The crude extract was fractionated by preparative TLC (EtOAc–hexane 4 : 1) to give a crude sample of **22**. This was further purified after treatment with CH_2N_2 (Et_2O solution) to give 0.1 mg of the methyl ester of **22**.

^1H NMR (600 MHz, CDCl_3) δ 5.95 (d, 1H, $J = 10.0$ Hz), 5.75 (dd, 1H, $J = 9.1, 6.2$ Hz), 5.55 (m, 1H), 4.28 (m, 1H), 3.68 (s, 3H), 2.50–2.20 (m, 6H), 1.80–1.20 (m, 10H), 1.16 (d, 3H, $J = 7.4$ Hz), 0.88 (d, 3H, $J = 7.0$ Hz).

Acknowledgements

The authors thank Dr Robert McDonald (University of Alberta) for crystallographic analyses, Dr Joanna Harris (University of Alberta) for performing the selective reduction of **10** to **11** and Karr-Hong Lee (University of Alberta) for isolating **19**. This work was supported by the Natural Sciences and Engineering Research Council of Canada, the Canada Research Chair in Bioorganic and Medicinal Chemistry, the Canada Foundation for Innovation, and the Alberta Science and Research Authority.

References

- (a) A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch and J. Springer, *Proc. Natl. Acad. Sci. USA*, 1980, **77**, 3957–3961; (b) A. Endo, *J. Antibiot.*, 1979, **32**, 852–854.
- (a) W. F. Hoffman, A. W. Alberts, P. S. Anderson, J. S. Chen, R. L. Smith and A. K. Willard, *J. Med. Chem.*, 1986, **29**, 849–852; V. F. Mauro and J. L. Macdonald, *DICP Ann. Pharmacother.*, 1991, **25**, 257–264; (b) for an overview of statins see M. Igel, T. Sudhop and K. vonBergmann, *Eur. J. Clin. Pharmacol.*, 2001, **57**, 357–364.
- (a) Y. Tsujita, M. Kuroda, Y. Shimada, K. Tanzawa, M. Arai, I. Kaneko, M. Tanaka, H. Masuda, C. Tarumi, Y. Watanabe and S. Fujii, *Biochimica. Biophys. Acta*, 1986, **877**, 50–60; (b) N. Serizawa, K. Nakagawa, K. Hamano, Y. Tsujita, A. Terahara and

- H. Kuwano, *J. Antibiot.*, 1983, **36**, 604–607; (c) for a review of pravastatin pharmacology see D. Mctavish and E. M. Sorkin, *Drugs*, 1991, **42**, 65–89.
- 4 A. Sutherland, K. Auclair and J. C. Vederas, *Curr. Opin. Drug Discovery Dev.*, 2001, **4**, 229–236.
- 5 J. Kennedy, K. Auclair, S. G. Kendrew, C. Park, J. C. Vederas and C. R. Hutchinson, *Science*, 1999, **284**, 1368–1372.
- 6 K. Auclair, A. Sutherland, J. Kennedy, D. J. Witter, J. P. Van den Heever, C. R. Hutchinson and J. C. Vederas, *J. Am. Chem. Soc.*, 2000, **122**, 11519–1120.
- 7 (a) For a review see C. R. Hutchinson, J. Kennedy, C. Park, S. Kendrew, K. Auclair and J. C. Vederas, *Antonie van Leeuwenhoek*, 2000, **78**, 287–295; (b) see also A. Endo, Y. Negishi, T. Iwashita, K. Mizukawa and M. Hirama, *J. Antibiot.*, 1985, **38**, 444–448; (c) A. Endo, K. Hasumi and S. Negishi, *J. Antibiot.*, 1985, **38**, 420–422.
- 8 (a) K. Wagschal, Y. Yoshizawa, D. J. Witter, Y. Q. Liu and J. C. Vederas, *J. Chem. Soc., Perkin Trans. 1*, 1996, 2357–2363; (b) Y. Abe, T. Suzuki, C. Ono, K. Iwamoto, M. Hosbuchi and H. Yoshikawa, *Mol. Genet. Genomics*, 2002, **267**, 636–646.
- 9 K. Auclair, J. Kennedy, C. R. Hutchinson and J. C. Vederas, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 1527–1531.
- 10 L. R. Treiber, R. A. Reamer, C. S. Rooney and H. G. Ramjit, *J. Antibiot.*, 1989, **42**, 30–36.
- 11 A. E. Decamp, T. R. Verhoeven and I. Shinkai, *J. Org. Chem.*, 1989, **54**, 3207–3208.
- 12 A. K. Willard and R. L. Smith, *J. Labelled Compd. Radiopharm.*, 1982, **19**, 337–344.
- 13 (a) For other examples of the synthesis of dihydrolovastatin see J. Schnaubelt, B. Frey and H. U. Reissing, *Helv. Chim. Acta*, 1999, **82**, 666–676; (b) C. M. Blackwell, A. H. Davidson, S. B. Launchbury, C. N. Lewis, E. M. Morrice, M. M. Reeve, J. A. R. Roffey, A. S. Tipping and R. S. Todd, *J. Org. Chem.*, 1992, **57**, 5596–5606; (c) S. Hanessian, P. J. Roy, M. Petrini, P. J. Hodges, R. Di Fabio and G. Carganico, *J. Org. Chem.*, 1990, **55**, 5766–5777.
- 14 G. Albers-Schonberg, H. Joshua, M. B. Lopez, O. D. Hensens, J. P. Springer, J. Chen, S. Ostrove, C. H. Hoffman, A. W. Alberts and A. A. Patchett, *J. Antibiot.*, 1981, **34**, 507–512.
- 15 W. Bartmann, G. Beck, E. Granzer, H. Jendralla, B. V. Kerekjarto and G. Wess, *Tetrahedron Lett.*, 1986, **27**, 4709–4712.
- 16 (a) M. F. Baltazar, F. M. Dickinson and C. Ratledge, *Microbiology (Reading, UK)*, 1999, **145**, 271–278; (b) S. Valenciano, J. R. DeLucas, A. Pedregosa, I. F. Monistrol and F. Laborda, *Arch. Microbiol.*, 1996, **166**, 336–341.
- 17 W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K. Sewing and U. Christians, *Drug Metab. Dispos.*, 1999, **27**, 173–179.
- 18 R. B. Silverman, *The Organic Chemistry of Enzyme Catalyzed Reactions*, Academic Press, San Diego, 2000, p. 204.
- 19 T. Nakamura, D. Komagata, S. Murakawa, K. Sakai and A. Endo, *J. Antibiot.*, 1990, **43**, 1597–1600.
- 20 P. R. Ortiz de Montellano and J. J. De Voss, *Nat. Prod. Rep.*, 2002, **19**, 477–493.
- 21 A. Endo and K. Hasumi, *J. Antibiot.*, 1985, **38**, 321–327.
- 22 G. Stork and D. E. Kahne, *J. Am. Chem. Soc.*, 1983, **105**, 1072–1073.